Bio Developments

© Getty Images

Cancer vaccine shows promising long-term survival data

By Isabel Cameron

Ultimovacs, a clinical-stage biotech developing novel immunotherapeutic cancer vaccines, has announced ‘encouraging’ overall survival (OS) data for its phase 1 clinical trial in malignant melanoma.

© Getty Images

Terumo BCT and BioCentriq to generate public CAR-T cell data

By Isabel Cameron

Terumo Blood and Cell Technologies, a medical tech company, and BioCentriq, a cell therapy contract development and manufacturing organization (CDMO), are working together to demonstrate the capabilities of Terumo’s automated cell and gene therapy platforms...

© Getty Images

Special Sponsored Newsletter

AGC Biologics: how to optimize early phase manufacturing

By Isabel Cameron

AGC Biologics is a global contract development manufacturing organization (CDMO) providing development and manufacturing services for protein-based biologics and advanced therapies.

© Getty Images

Fujifilm Diosynth builds advanced therapy manufacturing facility in UK

By Jonathan Smith

The contract development and manufacturing organization (CDMO) Fujifilm Diosynth Biotechnologies has completed a UK manufacturing facility for the production of advanced therapies including viral gene therapies, oncolytic viruses and viral vaccines for...

© Getty Images

Vaxess announces $9 million in funding for mRNA vaccine patch

By Isabel Cameron

Vaxess Technologies, a life sciences company developing a shelf-stable vaccine patch with potential for self-application, has announced an additional $9 million in venture capital funding, with investors including RA Capital, The Engine, and GHIC, and...

© Getty Images

Arrowhead highlights potential of RNAi in asthma at ERS 23

By Isabel Cameron

Arrowhead Pharmaceuticals has spotlighted the potential of RNA interference (RNAi) therapeutic candidates in the lungs, with a clinical late breaker and multiple pre-clinical presentations at this year’s European Respiratory Society (ERS) International...

© Getty Images

Kuano raises £1.8 million to accelerate quantum drug discovery

By Isabel Cameron

Kuano, a drug discovery company combining quantum mechanics with AI, has announced the close of its £1.8 million seed funding round, led by Mercia Ventures, and including ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory LLP, and other...

Follow us

Webinars